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AbstrACt
Introduction One of the most common distressing 
conditions experienced by breast cancer survivors is fear 
of cancer recurrence (FCR). There is, however, no standard 
intervention for ameliorating FCR. Our clinical experience 
and previous studies have suggested the potential 
benefits of problem-solving therapy (PST) and behavioural 
activation (BA). Given the huge number of cancer survivors 
and limited number of therapists to competently conduct 
PST and BA, we have developed PST and BA smartphone 
applications. This study aimed to evaluate the efficacy of 
the smartphone-based PST (Kaiketsu-App) and BA (Genki-
App) apps in reducing FCR in patients with breast cancer.
Methods and analysis The SMartphone Intervention to 
LEssen fear of cancer recurrence project is an open-label, 
individually randomised, parallel-group trial. Allocation 
will be managed by a central server using a computer-
generated random allocation sequence provided by an 
independent data centre. Participants will be randomised 
to smartphone-based intervention plus treatment as 
usual (TAU) or waitlist control with TAU alone. The 
primary endpoint of the study is the Japanese version 
of the Concerns About Recurrence Scale, which will be 
administered as an electronic patient-reported outcome on 
the patients’ smartphone after 8 weeks.
Ethics and dissemination The present study is subject 
to the ethical guidelines for clinical studies published by 
Japan’s Ministry of Education, Science and Technology and 
Ministry of Health, Labour and Welfare and the modified 
Act on the Protection of Personal Information as well as 
the ethical principles established for research on humans 
stipulated in the Declaration of Helsinki and further 
amendments thereto. The protocol was approved by the 
Institutional Review Board of Nagoya City University on 15 
January 2018 (ID: 60-00-1171).
trial status  The randomised trial, which commenced on 
2 April 2018, currently enrols participants. The estimated 
end date for this study is in March 2020. 
trial registration number UMIN000031140; Pre-results.
IntroduCtIon 
Worldwide, breast cancer is one of the most 
common cancers among women. In Japan, 
it is also the most common cancer among 
women, and the incidence is increasing. At 
present, approximately 90 000 women in 
Japan are annually diagnosed with breast 
cancer. Advances in early detection and indi-
vidualised medical treatment have improved 
strengths and limitations of this study
 ► This study is the first trial investigating the efficacy 
of smartphone-based psychological therapy for fear 
of cancer recurrence (FCR) among breast cancer 
survivors.
 ► Because many breast cancer survivors return to 
their households and work, easily accessible thera-
peutic interventions without hospital visits may offer 
benefits.
 ► This study focuses on younger breast cancer survi-
vors who are iPhone users; this focus could reduce 
the external validity of the findings obtained.
 ► The use of the waitlist control conditions may over-
estimate the efficacy of the smartphone-based 
psychotherapy.
 ► We will apply two types of psychotherapy and 
both interventions consist of complex, multifac-
torial components; thus, we cannot be certain 
which intervention and components are most ben-
eficial in managing FCR; however, we will adopt a 
mixed methods design to overcome those issues.
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the survival rate of patients with breast cancer. The current 
10-year survival rate for patients with breast cancer is over 
90%, which contributes to the increasing number of 
breast cancer survivors.1 
Thus, patients with breast cancer have on average 
a better prognosis than those with many other types of 
cancer; however, it has been suggested that many breast 
cancer survivors suffer from uncertainty, anxiety and fear 
over recurrence.2–4 Our previous study found that the 
most common unmet needs experienced by patients with 
ambulatory breast cancer are psychological—especially 
fear of cancer recurrence (FCR); over half of patients 
complained of such needs.5 Among patients with breast 
cancer, FCR is highly prevalent and is associated with 
poor quality of life.2 5–8
Accordingly, there is an urgent need for an appro-
priate intervention for FCR. However, there is no stan-
dard intervention for ameliorating FCR.8 Recent studies 
have demonstrated that the following can improve FCR 
among breast cancer survivors: mindfulness stress reduc-
tion (six weekly group sessions); cognitive–behavioural 
therapy (CBT; five individual face-to-face sessions and 
three e-consultations over a period of 3 months); and 
the novel theoretically based intervention of Conquer-
Fear, which includes attention training, metacognition, 
and acceptance and mindfulness (five individual face-to-
face sessions over 10 weeks).9–12 These interventions may 
be promising; however, one problem with this kind of 
intervention is the low participation rate owing to time 
and distance issues (eg, over 60% of potentially eligible 
subjects have been found to decline participation).9 11–14 
In addition, the number of therapists who can provide 
such specialised care may be severely limited, which is a 
serious problem in many countries.
Our past experience and some studies indicate the 
effectiveness of CBT, including problem-solving therapy 
(PST) and behavioural activation (BA), for FCR among 
breast cancer survivors (Momino, in press).15–17 We have 
demonstrated that patients’ problem-solving skills were 
significantly associated with FCR.15 Our hypotheses of 
their underlying mechanisms are that PST contributes 
to patients’ better coping with situations commonly trig-
gering FCR (eg, pain, exposure to news about cancer, 
regular visit to cancer hospital, and so on) and other 
stressful situations that increase FOR and that BA also 
improves FOR through distraction and through increased 
sense of mastery and pleasure. PST and BA are straight-
forward interventions that can be administered by less 
experienced therapists, including nurses.18 However, 
patients willing to undergo PST or BA are rarely able to 
do so even in well-resourced countries because a typical 
course of PST or BA consists of 8–12 face-to-face sessions 
lasting 1 or 1.5 hours led by a trained therapist.19–21
Though such programs seem promising, they appear 
to suffer limitations similar to those of the above-men-
tioned therapeutic interventions.9–12 Given the growing 
number of women annually diagnosed with breast cancer 
and the high prevalence among them of unmet needs 
of FCR, a completely novel approach to therapy provi-
sion is required. Recent studies have demonstrated the 
effectiveness of computerised CBT.22 23 In light of recent 
developments in information and communication tech-
nology (ICT), CBT delivered via smartphones may be a 
better treatment option for FCR—in terms of accessibility 
and portability—than a computer-based one.24 We have 
recently developed a smartphone CBT app, which teaches 
skills in BA and cognitive restructuring; we demonstrated 
its efficacy for antidepressant-resistant major depression 
in a randomised controlled trial.25 We have also developed 
PST programs as a smartphone app and demonstrated 
the acceptability and efficacy of the smartphone-based 
PST in a single-arm pilot study with breast cancer survi-
vors (Imai, submission). The purpose of the present 
randomised study is to examine the efficacy of smart-
phone-based PST and BA interventions to reduce FCR in 
patients with breast cancer in a randomised controlled 
trial. Since there is no specific standard intervention for 
ameliorating FCR as mentioned above and our research 
team’s discussion suggests that setting waitlist control will 
be more feasible than no intervention, waitlist control is 
used as a comparator.
MEthods And AnAlysIs
This protocol has been written in accordance with the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials guideline.26
trial design
The present study is an individually randomised, paral-
lel-group trial (figure 1). An independent data centre 
will provide computer-generated random allocation 
sequences. The allocation sequences are maintained 
centrally, and the results of the assignment will be sent 
automatically to the study participants by email. The 
participants are randomised to smartphone-based inter-
vention plus treatment as usual (TAU) or waitlist control 
with TAU alone. TAU means general treatment and/or 
care commonly provided by each patient’s hospital (eg, 
nurse’s support, and so on).
Interventions: smartphone-based Pst (Kaiketsu-App) and bA 
(Genki-App)
PST provides patients with a structured strategy for 
solving their problems. PST includes the following five 
steps27: (1) identification, definition and breakdown of 
the problem; (2) establishing achievable goals; (3) gener-
ating solutions; (4) evaluating and choosing the solution; 
and (5) implementing the chosen solution and evalu-
ating the outcome after implementation.
The smartphone-based PST program, called Kaiket-
su-App (‘Kaiketsu’ means ‘Solution’ in Japanese), for 
iPhones and iPads (Apple, Cupertino, CA, USA) was 
developed for this study (figure 2). The development was 
based on our empirically supported PST manual.17 Kaiket-
su-App comprises nine sessions (online supplementary 
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table): three introductory sessions; four sessions about 
learning the PST in five steps; one session of actual 
training; and one concluding session. The shortest time 
necessary to complete Kaiketsu-App is 2 weeks. The 
main program consists of dialogues between charac-
ters, who explain the principles and skills of PST. After 
the first session, participants have to do homework. The 
time necessary to complete one session is approximately 
30 min.
BA intervention was developed based on the hypothesis 
that anxiety can lead to less pleasurable behaviour and 
more sedentary life, which then may lead to worsening 
anxiety.27
The smartphone-based BA program Genki-App 
(‘Genki’ means ‘Energy or Vitality’ in Japanese) for 
iPhones and iPads (figure 3) was developed as part of the 
smartphone-based CBT program which was developed for 
our previous study.28 Genki-App consists of two sessions 
(online supplementary table), and approximately 30 min 
is needed to complete each session: one is outline and 
introduction of BA therapy including two types of activa-
tion (eg, do pleasurable activity again and challenge new 
activity) and their actual training. (Genki-App includes 
a self-learning sheet for planning and doing pleasur-
able and new activity, and for evaluating achievement 
after conducting its activity.) The other is review of the 
session, learning knack of BA (start an activity to be able 
to conduct by yourself; divide big aim into some smaller 
ones; plan a schedule to conduct an activity; image a situa-
tion when you can do it well) and concluding session. The 
shortest time necessary to complete Genki-App is also 2 
weeks. The Genki-App program also mainly consists of 
dialogues between characters and homework.
Over the 8-week period of the programs, participants 
are encouraged to complete the sessions and home-
work through automated email reminders once a week. 
Although we cannot know the contents of homework 
for privacy security, treatment adherence (eg, times and 
length of using each App) can be checked by Google 
Analytics.
Participants
The inclusion criteria for participants are as follows: (1) 
diagnosis of breast cancer and awareness of the cancer 
diagnosis; (2) ages 20–49 years; (3) 1 year following breast 
surgery; (4) currently disease free; (5) ability to complete 
an electronic patient-reported outcome (e-PRO) using an 
iPhone or iPad; and (6) being an iPhone or iPad user 
and having an apple ID to install applications using App 
Store. We limit the patients’ age to 20–49 years because 
one study and our previous investigation demonstrated 
that individuals of that age are at high risk of FCR and that 
more than 50% of such people have smartphones.8 29 30
The exclusion criteria for participants are as follows: 
(1) having active, serious physical disease that affects 
household and light work and a history or current history 
Figure 1 Participant flow diagram. BA, behavioural activation; PST, problem-solving therapy.
4 Akechi T, et al. BMJ Open 2018;8:e024794. doi:10.1136/bmjopen-2018-024794
Open access 
of cancer other than breast cancer; (2) inability to under-
stand Japanese; (3) currently undergoing follow-up and 
treatment in a psychiatry department or by other mental 
health professionals; (4) patients who have previously 
undergone structured PST, BA therapy or CBT; and (5) 
judged inappropriate for participation by the researchers 
(eg, identity theft, duplicate entry, and so on).
ProCEdurEs
newly developed research management system
To lessen patient inconvenience in visiting hospital for 
this study and oncologists’ workload in enrolling study 
participants, we developed a research management 
system making full use of ICT technology (figure 4). The 
study’s website (https:// smile- project. org/) provides 
information about this study. A poster briefly introducing 
the study and including a QR code for the website has 
been put up in 10 core cancer hospitals in Japan and study 
information will be disseminated repeatedly by using 
several social networking systems (eg, Facebook, patient’s 
mailing list, and so on). The website explains the purpose 
of the study, eligibility criteria and methods used; it also 
features a video briefly introducing the study as well as 
providing full written information about it. Potential 
participants who are interested in the study can email the 
study’s central office, and clinical research coordinators 
(CRC) at the central office ascertain their eligibility by 
telephone (table 1).
Electronic informed consent and randomisation at week 0
After screening, the CRCs will seek to obtain the subjects’ 
electronic informed consent (e-consent) via e-PRO 
system at week 0. Participants will be requested to upload 
a picture of identification materials. (Patients will be 
especially encouraged to attach a photo of the ID card of 
the hospital where they made regular follow-up visits for 
breast cancer.) This e-consent procedure is in accordance 
Figure 2 Kaiketsu-App. Application for smartphone-based 
problem-solving treatment.
Figure 3 Genki-App. Application for smartphone-based 
behavioural activation.
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with the guidance of the US Food and Drug Administra-
tion.31 Original informed consent material is shown in 
the online supplementary appendix.
After providing e-consent and completing the baseline 
investigation by e-PRO, the participants will be randomly 
allocated to either the smartphone-based PST and BA 
group or the waitlist control group in a 1:1 ratio using the 
electronic data capturing (EDC) web program at the data 
management centre (figure 1). The random allocation 
will therefore be concealed.
If a participant is allocated to the intervention group, 
they will receive a password unique to them for using 
Kaiketsu-App and Genki-App. On entering the password, 
participants will be able to proceed to the sections for 
Kaiketsu-App and Genki-App. If participants are allocated 
to the control group, they will be informed that use of 
Kaiketsu-App and Genki-App can be resumed if they wish 
after week 8.
data management, central monitoring, data monitoring and 
auditing
We will collect all data except qualitative interview data 
through e-PRO; we will obtain qualitative interview data 
by telephone. (See below for details.) If participants 
fail to provide their responses regarding FCR, a CRC 
blinded to the assignment will telephone the subjects 
to elicit their answers. Data management and central 
monitoring will be performed using the EDC. The 
EDC consists of two different and independent parts, 
one including personal information and the other 
including trial-related data (eg, assignment, outcomes, 
and so on) for security. Since the psychological interven-
tion provided by apps will not be invasive and also not 
produce serious harms, data monitoring committee will 
not be organised. Similarly, auditing is not also planned 
for this study.
Figure 4 Study management system. e-consent, electronic informed consent; e-PRO, electronic patient-reported outcome; 
FAQ, frequently asked questions. 
Table 1 Schedule for outcome measurement
Assessment 
Time points
0 week 2 weeks 4 weeks 8 weeks 24 weeks
Understanding of the e-consent ●
Characteristic ●
CARS-J, HADS ● ● ● ● ●*
FCRI, SCNS-SF34, PTGI-J ● ● ●*
Satisfaction with interventions ●*
Qualitative assessment of apps ●*
*These would be evaluated only for intervention group.
CARS-J, Japanese version of the Concerns About Recurrence Scale; FCRI, Fear of Cancer Recurrence Inventory; HADS, Hospital Anxiety 
and Depression Scale; PTGI-J, Post-traumatic Growth Inventory-Japanese version; SCNS-SF34: Short-Form Supportive Care Needs Survey 
questionnaire.
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data set available
The deidentified anonymised data set will be uploaded to 
UMIN-ICDR (http://www. umin. ac. jp/ icdr/ index- j. html) 
and researchers approved by the steering committee will 
be able to have access to the data set.
trial period: weeks 0–8
For participants allocated to the intervention group, 
an automated email encouraging their adherence to 
Kaiketsu-App and Genki-App will be sent every week for 
8 weeks. The research team can check the patient’s prog-
ress (number of times and duration using each applica-
tion) with Kaiketsu-App and Genki-App using Google 
Analytics. At weeks 2, 4 and 8, participants will receive 
an email encouraging them to record their responses on 
e-PRO.
Follow-up period: weeks 8–24
Participants allocated to the control group can resume 
the Kaiketsu-App and Genki-App if they wish. At week 
24, participants allocated to the intervention group will 
receive an email encouraging them to provide their 
responses on e-PRO.
Concomitant treatments
There is no restriction on concomitant treatments.
stopping rules for participants
Discontinuation of protocol treatment.
If a participant meets any of the following conditions, 
the research team can discontinue the Kaiketsu-App and 
Genki-App. However, the participant will not be consid-
ered to have dropped out of the trial at that stage and 
will receive the protocol assessments: (1) the participant 
wishes to stop the protocol treatment; (2) the research 
team judges that the risk of the protocol treatment is 
greater than the benefit for any reason; (3) the research 
team judges that it is difficult to continue the protocol 
treatment because of clinical deterioration; and (4) the 
research team judges that it is inappropriate to continue 
the protocol treatment for any reason (eg, when identity 
theft, duplicate entry, and so on, are detected).
stopping assessment
If a participant withdraws consent for assessment, she will 
not be followed up. Subjects will be excluded from the 
intention-to-treat (ITT) cohort of the trial only if their 
characteristics are found to meet any exclusion criteria at 
baseline (eg, age over 50 years) after participation.
Assessment measures
Table 1 shows the schedule for outcome measurement.
Primary outcome measure
Fear of recurrence: Japanese version of the Concerns About 
Recurrence Scale
Originally developed in the USA, the Japanese version 
of the Concerns About Recurrence Scale (CARS-J) is a 
26-item self-report scale to measure fear of recurrence of 
breast cancer.32 The reliability and validity of CARS-J have 
been confirmed among Japanese patients with breast 
cancer.33 CARS-J assesses the overall fear of breast cancer 
recurrence and four domains of specific fear of recur-
rence. Overall, fear comprises four items: questions on 
frequency; potential for upset; consistency; and intensity 
of fear. The overall fear score with CARS-J is our primary 
outcome. The range of possible scores for overall fear is 
4–24; a higher score indicates greater fear of recurrence.
Secondary outcome measures
Fear of Cancer Recurrence Inventory-Short Form
The Fear of Cancer Recurrence Inventory-Short Form 
(FCRI-SF) is a 9-item self-report scale originally devel-
oped in Canada.34 35 The FCRI evaluates the presence 
and severity of intrusive thoughts associated with FCR: 
scores range from 0 to 36; a higher score indicates severe 
FCR. Unlike with CARS-J, the FCRI-SF can measure fear 
of recurrence of any type of cancer. The Japanese version 
of the FCRI-SF was developed after obtaining permission 
from the original author and using a forward-backward 
translation process. In this study, the measure will be 
included as a secondary outcome after its validity and reli-
ability have been ascertained.
Psychological distress: hospital Anxiety and depression scale
The Hospital Anxiety and Depression Scale (HADS), a 
self-report questionnaire comprising 14 items, was devel-
oped for use with patients with medical illness. The 
HADS consists of an anxiety and a depression subscale 
(0–21 points each). The total score ranges from 0 to 42; 
a higher score indicates more severe depression and 
anxiety.36 The Japanese version of the HADS has been 
validated for cancer populations.37
Patients’ perceived needs: short-Form supportive Care needs 
survey questionnaire
The Short-Form Supportive Care Needs Survey question-
naire (SCNS-SF34) is a self-administered instrument for 
assessing the perceived needs of patients with cancer.38 
The SCNS-SF34 comprises 34 items covering five domains 
of need: psychological; health system and information; 
physical and daily living; patient care and support; and 
sexuality. The total score is obtained by summing all the 
subscales (range 34–170). A higher score indicates a 
higher perceived need. The validity and reliability of the 
Japanese version of SCNS-SF34 have been established.39
Post-traumatic Growth Inventory-Japanese version
The Post-traumatic Growth Inventory (PTGI) is a 21-item 
self-report scale originally developed in the USA.40 The 
PTGI includes items that measure positive psychological 
change experienced as a result of struggle with major life 
crises or traumatic events. The PTGI-J consists of four 
subscales: relating to others; new possibilities; personal 
strength; and spiritual change and appreciation of life. 
The total score ranges from 0 to 90; a higher score indi-
cates more positive changes.41
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satisfaction with intervention
To assess patients’ perceived satisfaction with the inter-
vention, we ask two additional items. The items are as 
follows. (1) ‘Please rate your satisfaction with the treat-
ment in meeting your needs during the past 2 months 
by assigning it a score from 0 to 100; a score of 100 indi-
cates complete satisfaction. A score of 60 is considered 
the passing level.’ (2) ‘Please rate your overall satisfaction 
with the treatment during the past 2 months by assigning 
it a score from 0 to 100; a score of 100 indicates complete 
satisfaction. A score of 60 is considered the passing level.’ 
A lower score indicates lower satisfaction. We used this 
method in our previous study.42
understanding e-consent
Ten questions will be asked at week 0 related to the partic-
ipants’ understanding of e-consent: purpose of the study; 
randomisation; voluntary participation; duration of study; 
risks and benefits of study participation; free withdrawal 
anytime from the study; contact method for questions 
and more detailed information about the study; method 
of participant identification (uploading a photo of the 
hospital registration card); which of the video or written 
documentation in the website was the more helpful in 
understanding the study contents; and free opinions 
regarding e-consent.
Qualitative evaluation of intervention
The intervention will consist of multiple complex compo-
nents; accordingly, simple structured telephone interviews 
will be conducted at 8 weeks for approximately 30 subjects 
willing to participate in this additional survey to evaluate 
the perceived usability and/or merit of the complex inter-
vention. The interview items will be as follows. (1) ‘Please 
talk freely about the usefulness of the smartphone PST 
and smartphone behavioral intervention.’ (2) ‘Please talk 
freely about the usefulness of each of the five steps of the 
smartphone PST and give your reasons for your opin-
ions.’ (3) ‘Please talk freely about the usefulness of the 
two parts of the smartphone behavioral intervention and 
give your reasons for your opinions.’ (4) ‘Please talk freely 
about the effectiveness and harms of the intervention, for 
example, the regular encouraging e-mail, and if any other 
components contributed to improving or deteriorating 
your fear of recurrence.’ If the participants permit, the 
answers will be recorded using a voice recorder.
Sociodemographic and biomedical factors e-PRO will 
also be used to obtain information about the patients’ 
sociodemographic and biomedical status (marital status, 
level of education and employment status) and biomed-
ical information (physical function, time since diagnosis, 
clinical stage and anticancer treatment).
harms
No specific and serious adverse events are presumed in 
participants who use the Kaiketsu-App and Genki-App. 
However, using these apps might lead to psycholog-
ical distress in some participants depending on their 
psychological state. We will evaluate these potential 
adverse events by qualitative evaluation of intervention as 
mentioned before.
Compensation
Our previous and preliminary trials suggest that few harms 
occur in this trial. However, if any health hazards occur, 
these will be covered by the National Health Insurance.
data analysis
Primary analyses
To examine the treatment effect parameters of all 
randomly assigned subjects in the primary analysis 
set according to the ITT principle, we will analyse the 
primary outcome (CARS-J score at weeks 2, 4 and 8) using 
a generalised linear model with unstructured covariance 
and robust SEs. The fixed effects are CARS-J score at base-
line, treatment allocation (intervention vs control), time 
(2, 4 and 8 weeks as categorical variable) and treatment-
by-time interaction; the random effects are subjects (as 
intercepts). The primary outcome of interest is the differ-
ence in CARS-J scores between the two groups at week 8. 
A two-sided p value <0.05 will be used to indicate statis-
tical significance.
Secondary analyses
We will perform secondary analyses to supplement our 
primary analysis and to obtain a clearer understanding 
of our clinical questions. The secondary analyses will use 
models similar to that of the primary analysis and will 
also examine data for the secondary outcome measures. 
The secondary analyses will include an assessment of the 
validity and reliability of FCR-J. These analyses will be 
conducted for exploratory purposes.
Interim analyses
We do not plan any interim analysis.
sample size estimation
Our previous phase II study revealed that the mean 
CARS-J scores were 12.8 at preintervention (baseline), 
12.4 at 4 weeks and 11.2 at 8 weeks (Imai, submission). We 
assumed the following: the mean CARS-J score at 2 weeks 
would be 12.6; the overall CARS-J scores in the control 
arms would not change (12.8 at 0, 2, 4 and 8 weeks); 
the variance of the score would be 30 at all times; and 
the intraclass correlation would be 0.82 (ie, we assumed 
a compound symmetry working covariance structure). 
Thus, for a sample size based on 0.8 power to detect a 
significant difference at p=0.05 (two sided), 211 partici-
pants would be required for each arm. Assuming that 5% 
of the initial entries would drop out, we would need to 
recruit 444 participants into the trial.
Publication policy
The protocol paper and study results will be submitted to 
peer-reviewed journals. The first author of the main paper 
will be a member of the steering committee (authors of 
the protocol paper). Another person could be the first 
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author if approved by the steering committee. The list 
of coauthors will be determined before submitting each 
paper.
study period
The study period of this trial will be from April 2017 to 
March 2020; the participant entry period will be April 
2018 to September 2019.
Patient and public involvement statement
The study protocol was designed with a patient (breast 
cancer survivor) and she participated in this study as 
a researcher. She appropriately discussed with other 
patients when a patient’s preferences and/or opinions 
should be considered. She will play a same role on imple-
menting the study. Thus, patients were and will always 
be involved in the study. Results of the study will be shown 
in the study homepage.
Ethics and dissemination
The present study is subject to ethical guidelines for clin-
ical studies published by Japan’s Ministry of Education, 
Science and Technology and Ministry of Health, Labour 
and Welfare and the modified Act on the Protection of 
Personal Information as well as the ethical principles 
established for research on humans stipulated in the 
Declaration of Helsinki and further amendments thereto.
If important protocol modifications are needed, the 
investigators will discuss them and report to the review 
board for approval.
With regard to dissemination, the results obtained 
will be submitted for publication in peer-reviewed jour-
nals. The main and relevant findings will be presented at 
conferences.
dIsCussIon
To our knowledge, the present study is the first trial 
investigating the efficacy of smartphone-based psycholog-
ical therapy for fear of recurrence among breast cancer 
survivors. Considering the huge number of breast cancer 
survivors and low participant rate with other types of 
therapeutic interventions, smartphone-based psycho-
logical therapy may offer a more accessible option. As 
many cancer survivors return to their households and 
to work, easily accessible therapeutic interventions may 
offer additional benefits in managing fear of recur-
rence. The present study focuses on younger patients 
with breast cancer who are iPhone users. However, many 
other patients suffering from fear of recurrence use 
other types of smartphones (eg, Android); in addition, 
including patients aged 50 years and above would consti-
tute a broader targeted population. If the efficacy of the 
smartphone-based intervention program among our 
participants is confirmed, the program will have prom-
ising applicability in real clinical settings.
The present study has some methodological limitations. 
First, not all patients who are interested in and willing to 
use Kaiketsu-App and Genki-App possess a smartphone. 
This may weaken the applicability of the results from this 
trial to all patients with breast cancer with fear of recur-
rence. Especially, the results may not be applicable to 
patients in low/middle-income countries and to those 
with poor ICT literacy.
Second, we will use a waitlist control as the compar-
ator owing to feasibility and ethical considerations. The 
odds of response was found to be statistically significantly 
greater for no treatment than the waitlist.43 The waitlist 
may therefore lead to some overestimation of the efficacy 
of smartphone-based psychotherapy.
Third, we will apply two types of psychotherapy—BA 
and PST—as interventions. Both psychotherapeutic 
interventions consist of complex, multifactorial compo-
nents. Thus, if the interventions prove superior to the 
waitlist controls, we cannot determine which interven-
tion and components are most efficacious or beneficial 
in managing fear of recurrence. However, to overcome 
this limitation, we will adopt a mixed methods design and 
can check adherence with each intervention (detailed in 
‘Methods and analysis’) so that we can identify the most 
useful components of the interventions.
Fourth, we will request that participants upload 
images for identification (they will be especially 
encouraged to attach a photo of the hospital regis-
tration card) to avoid individuals masquerading as 
patients with breast cancer. However, possible decep-
tion cannot be completely prevented in our recruit-
ment system.
Finally, lack of the third group, which is the in-person 
PST and BA treatment arm, would lessen the impact of 
this study. If we set the in-person PST and BA treatment 
arm to compare effect sizes in this group with the other 
two groups, we would be able to dissect the specific mech-
anisms of change.
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